Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TX 200

Next Previous
X
Search
Drug Profile

TX 200

Alternative Names: ENTX-SOT; HLA-A2 CAR-Treg - TxCell; HLA-A2-specific CAR-Treg cell therapy - TxCell; TX-200; TX200-TR101

Latest Information Update: 18 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of British Columbia
  • Developer Sangamo Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Transplant rejection

Most Recent Events

  • 18 Mar 2024 TX 200 is available for licensing as of 13 Mar 2024. https://www.sangamo.com/programs/#collaborations
  • 10 Mar 2023 Phase-II clinical trials in Transplant rejection (Prevention) in Netherlands (IV) (EudraCT2022-002440-40)
  • 08 Feb 2023 Phase-II clinical trials in Transplant rejection (Prevention) in Germany (IV) (EudraCT2022-002440-40)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top